Kodiak Sciences Inc.
NASDAQ: KOD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Victor Perlroth
- Employees
- 109
- Headquarters
- Palo Alto, United States
- IPO year
- 2018
- Market cap
- $1.9B
- Website
- https://kodiak.com
Loading KOD…
Loading profile data…Frequently asked questions about KOD
What does Kodiak Sciences Inc. (KOD) do?
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is cu...
Where does KOD trade?
Kodiak Sciences Inc. (KOD) trades on the NASDAQ Global Market.
What sector is KOD in?
Kodiak Sciences Inc. (KOD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kodiak Sciences Inc.?
Victor Perlroth is the chief executive officer of Kodiak Sciences Inc. (KOD).
Where is Kodiak Sciences Inc. headquartered?
Kodiak Sciences Inc. is headquartered in United States.
Does KOD pay a dividend?
Kodiak Sciences Inc. (KOD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KOD go public?
Kodiak Sciences Inc. (KOD) completed its initial public offering in 2018.